BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33166016)

  • 21. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database.
    Murphy CT; Galloway TJ; Handorf EA; Wang L; Mehra R; Flieder DB; Ridge JA
    Cancer; 2015 Apr; 121(8):1204-13. PubMed ID: 25490875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy for head and neck squamous cell carcinoma].
    Lecocq M; Poncin A; Sautois B
    Rev Med Liege; 2021 May; 76(5-6):398-402. PubMed ID: 34080370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
    Yu Y; Lee NY
    Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
    Suzuki K; Hayashi R; Ebihara M; Miyazaki M; Shinozaki T; Daiko H; Sakuraba M; Zenda S; Tahara M; Fujii S
    Jpn J Clin Oncol; 2013 Dec; 43(12):1210-7. PubMed ID: 24031082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prior chemoradiotherapy and pathological perineural invasion predict the survival outcomes of salvage surgery in head and neck squamous cell carcinoma.
    Akali NR; Buggaveeti R; Sukumaran SV; Balasubramanian D; Iyer S; Thankappan K
    Head Neck; 2021 Mar; 43(3):874-883. PubMed ID: 33219731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased pathologic upstaging with rising time to treatment initiation for head and neck cancer: A mechanism for increased mortality.
    Xiao R; Ward MC; Yang K; Adelstein DJ; Koyfman SA; Prendes BL; Burkey BB
    Cancer; 2018 Apr; 124(7):1400-1414. PubMed ID: 29315499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
    León X; Agüero A; López M; García J; Farré N; López-Pousa A; Quer M
    Auris Nasus Larynx; 2015 Apr; 42(2):145-9. PubMed ID: 25459494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable complete response rates following radiotherapy and immunotherapy combination in recurrent and metastatic head and neck squamous cell carcinoma: A retrospective single-centre cohort study.
    Khera R; Feeney L; Swinton M; Rack S; Sykes A; Metcalf R
    Clin Otolaryngol; 2022 Sep; 47(5):606-610. PubMed ID: 35737806
    [No Abstract]   [Full Text] [Related]  

  • 29. [Ⅰ. Photo-Immunotherapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck].
    Sano D; Oridate N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):775-780. PubMed ID: 37496220
    [No Abstract]   [Full Text] [Related]  

  • 30. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
    Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer.
    Huo M; Panizza B; Bernard A; Porceddu SV
    Oral Oncol; 2018 Feb; 77():43-48. PubMed ID: 29362125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.
    Breheret M; Lubgan D; Haderlein M; Hecht M; Traxdorf M; Schmidt D; Müller S; Kitzsteiner C; Kuwert T; Iro H; Fietkau R; Semrau S
    Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):245-254. PubMed ID: 31583430
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    van den Bosch S; Doornaert PAH; Dijkema T; Zwijnenburg EM; Verhoef LCG; Hoeben BAW; Kasperts N; Smid EJ; Terhaard CHJ; Kaanders JHAM
    Radiother Oncol; 2020 Jan; 142():107-114. PubMed ID: 31439447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer.
    Graboyes EM; Garrett-Mayer E; Ellis MA; Sharma AK; Wahlquist AE; Lentsch EJ; Nussenbaum B; Day TA
    Cancer; 2017 Dec; 123(24):4841-4850. PubMed ID: 28841234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known.
    Peltenburg B; Driessen JP; Vasmel JE; Pameijer FA; Janssen LM; Terhaard CHJ; de Bree R; Philippens MEP
    Eur Radiol; 2020 Feb; 30(2):1228-1231. PubMed ID: 31529258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck.
    Manohar PM; Sapir E; Bellile E; Swiecicki PL; Pearson AT; Prince ME; Shuman AG; Bradford CR; Chepeha DB; Wolf GT; Eisbruch A; Worden FP; Spector ME
    Otolaryngol Head Neck Surg; 2017 Dec; 157(6):995-997. PubMed ID: 28809131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunotherapy for head and neck squamous cell carcinoma].
    Chen J; Chen M; Wu HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful use of a therapeutic trial of graduated volume and dose escalation for postoperative head and neck radiotherapy in a Fanconi anemia patient.
    Lewis LM; Tang AL; Wise-Draper TM; Myers KC; Greenberger JS; Takiar V
    Head Neck; 2020 Oct; 42(10):E16-E22. PubMed ID: 32770810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.